A pharmaceutical composition for ocular administration comprising a peptide drug

The present invention relates to a pharmaceutical composition for ocular administration, and pharmaceutical uses of the pharmaceutical composition for anti-inflammatory purposes or for the prevention or treatment of macular degeneration. According to an embodiment, the pharmaceutical composition comprises: a peptide represented by Hyp-Gly-Gln-Glu-Aib-Leu-Ala as an active ingredient; an oil selected from a group consisting of diethylene glycol monoethyl ether, medium chain glycerides, and propylene glycol dicaprylate/dicaprate, and any combinations thereof; a surfactant selected from a group consisting of polyoxyl-35 castor oil, polysorbate 80, polyethylene glycol 400, propylene glycol, cottonseed oil, castor oil, and any combinations thereof; and water. The pharmaceutical composition is provided in a naanoemulsion type with an average diameter of contained particles of 200 nm or less. The present invention provides a pharmaceutical composition for ocular administration that contains a peptide drug as an active ingredient and can be delivered to the retina when administered as an eye drop. 일 양상은 활성성분으로서 Hyp-Gly-Gln-Glu-Aib-Leu-Ala로 표시되는 펩타이드; 디에틸렌 글리콜 모노에틸 에테르, 미디움 체인 글리세라이드, 및 프로필렌 글리콜 디카프릴레이트/디카프레이트, 및 이들의 임의의 조합으로 구성된 군에서 선택된 오일; 폴리옥실-35 피마자유, 폴리솔베이트 80, 폴리에틸렌글리콜 400, 프로필렌 글리콜, 면실유, 피마자유, 및 이들의 임의의 조합으로 구성된 군에서 선택된 계면활성제; 및 물을 포함하고, 함유된 입자의 평균 직경이 200 nm 이하인 나노에멀젼 형태의 안구 투여용 약학 조성물, 및 그 약학 조성물의 항염 또는 황반변성의 예방 또는 치료를 위한 의약 용도에 관한 것이다.